About
CervoMed is a clinical stage company dedicated to the development and commercialization of drug treatments for neurodegenerative diseases with a focus on the early stages of the neurodegenerative process.
Until August 2023, CervoMed was known as EIP Pharma Inc. EIP Pharma Inc is now a wholly-owned subsidiary of CervoMed.
We believe the neurodegenerative process, in the early stages, is primarily comprised of neuroinflammation-induced damage to synapses, which are the interconnections between nerve cells, or neurons. Our lead product candidate, neflamapimod, is currently in clinical development as a disease-modifying treatment for neurodegenerative diseases, such as dementia with Lewy Bodies and early Alzheimer’s disease. In addition, pre-clinical data supports the potential role of neflamapimod in recovery after stroke.
We have assembled a highly experienced leadership team to develop and commercialize innovative drug treatments for dementia with Lewy bodies, Alzheimer’s disease and other central nervous system disorders.
CervoMed
Medicines for the Brain
Are you a patient, caregiver, clinician or professional and want to learn more about CervoMed’s approach? Please contact us.
Contact Us